Patents by Inventor D. Bennett

D. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060140928
    Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
    Type: Application
    Filed: February 22, 2006
    Publication date: June 29, 2006
    Applicant: Biomarin Pharmaceutical Inc.
    Inventors: D. Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph Zimmermann
  • Publication number: 20050191288
    Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
    Type: Application
    Filed: May 2, 2005
    Publication date: September 1, 2005
    Applicant: Biomarin Pharmaceutical Inc.
    Inventors: D. Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph Zimmermann